Trial Profile
A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination With Trastuzumab (Herceptin) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2006 Status change
- 30 Aug 2005 New trial record.